U.S. pharma giant copyright scrapped two experimental weight loss drugs final 12 months—a when-daily tablet, lotiglipron, resulting from elevated liver enzymes and also a twice-everyday capsule, danuglipron, as a result of potent side effects—but CEO Albert Bourla has explained the c